Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 15, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2021 after the close of market on Monday, February 28, 2022 .
View HTML
Toggle Summary New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
Findings shared at 2022 ASCO GU Symposium are from the first late-stage clinical study validating any gene-expression test for this patient group SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 14, 2022-- Veracyte, Inc . (Nasdaq: VCYT) announced that new data validating the clinical utility of
View HTML
Toggle Summary Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 8, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on
View HTML
Toggle Summary Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 31, 2022-- Veracyte, Inc . (Nasdaq: VCYT) today announced that six abstracts highlighting new data for the company’s Decipher urologic cancer tests will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium, taking place in San
View HTML
Toggle Summary New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
Findings demonstrate genomic test’s expanded clinical utility in evaluating patients with lung nodules whose bronchoscopy results are inconclusive SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 24, 2022-- Veracyte, Inc. (Nasdaq: VCYT) announced the publication of new data that suggest the
View HTML
Toggle Summary Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
Tina Nova , Ph.D., Appointed President of CLIA U.S. Business Stephane Debono Named General Manager of IVD and EMEA Organizations Giulia C. Kennedy , Ph.D., Named Global Chief Scientific Officer and Chief Medical Officer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 6, 2022-- Veracyte, Inc .
View HTML
Toggle Summary Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary
View HTML
Toggle Summary Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
Only Test of Its Kind to Be Recommended for Use in All Swedish Healthcare Regions Without Restrictions SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 24, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that the Swedish Medical Technologies Product (MTP) Council has recommended the
View HTML
Toggle Summary Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
Brightplex technology is designed to enable biopharmaceutical researchers to assess the complex tumor micro-environment to aid in development of new therapeutics SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 13, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from three
View HTML
Toggle Summary Veracyte Announces Third Quarter 2021 Financial Results
Total Revenue of $60.4 Million and Volume of 20,972 Tests Company Launches Percepta Nasal Swab and Decipher Bladder Genomic Tests; Completes Acquisition of HalioDx Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 9, 2021-- Veracyte, Inc.
View HTML